Trial Profile
ODYSSEY: A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy of Tradipitant in Treating Inflammatory Lung Injury and Improving Clinical Outcomes Associated With Severe or Critical COVID-19 Infection
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Tradipitant (Primary) ; Tradipitant (Primary)
- Indications COVID 2019 infections; COVID-19 pneumonia
- Focus Registrational; Therapeutic Use
- Acronyms COVIDL1; ODYSSEY
- Sponsors Vanda Pharmaceuticals
- 01 Sep 2021 Results reporting carriers of stop-gain IFNAR2 (NM_000874:exon9:c.C966A:p.Y322X) in cohort of severe COVID-19 patients published in the Journal of Global Antimicrobial Resistance
- 03 Aug 2021 Primary endpoint has not been met. (Time to improvement on a 7-point ordinal scale as compared to baseline), according to a Vanda Pharmaceuticals media release.
- 03 Aug 2021 According to a Vanda Pharmaceuticals media release, company will continue the genetics component of the study with the goal of identifying genetic susceptibility factors contributing to the incidence of severe pneumonia among patients infected with the SARS-CoV-2 virus.